
Biocon Secures U.S. FDA Approval for Pebrilzo™ (Pertuzumab-qcay), Its Fifth Oncology Biosimilar, Expanding Access to HER2-Positive Breast Cancer Treatment
Biocon Limited, an innovation-led global biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta® (pertuzumab), for the treatment of HER2-positive breast cancer. The approval represents another significant milestone in Biocon’s expanding oncology business and strengthens its position in the global biosimilars market.
Pebrilzo is a monoclonal antibody designed to target human epidermal growth factor receptor 2 (HER2), a protein that plays an important role in the growth and survival of certain cancer cells. In patients with HER2-positive breast cancer, increased expression of the HER2 protein or amplification of the HER2 gene can contribute to the development and progression of tumors. Pertuzumab works by binding to the HER2 receptor and interfering with signaling pathways involved in cancer cell growth.
The FDA approval adds another important treatment option to Biocon’s oncology portfolio and reinforces the company’s commitment to developing and commercializing high-quality, affordable biologic medicines. Biosimilars are highly similar versions of previously approved biologic medicines, offering the potential to broaden treatment access while supporting healthcare systems in managing the costs associated with advanced therapies.
The approval of Pebrilzo is particularly important for patients with HER2-positive breast cancer, a subtype associated with aggressive disease progression and a substantial need for effective targeted treatment options. By expanding its portfolio of oncology biosimilars, Biocon aims to address the growing demand for biologic medicines and contribute to improving access to cancer care in the United States and other international markets.
Shreehas Tambe, CEO and Managing Director of Biocon Limited, highlighted the importance of the FDA decision, describing it as another major achievement in the company’s efforts to expand access to high-quality biosimilars.
“The U.S. FDA approval of PEBRILZO, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, PEBRILZO strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines,” Tambe said.
The latest regulatory milestone demonstrates Biocon’s continued progress in developing biosimilar versions of established biologic therapies for major disease areas. The company has been expanding its presence in oncology through a combination of commercialized products, regulatory achievements and pipeline investments. The addition of pertuzumab further broadens its portfolio of targeted cancer treatments.
European Regulatory Progress Strengthens Pebrilzo’s Global Position
The U.S. FDA approval follows positive regulatory progress for Biocon’s pertuzumab biosimilar in Europe. In September 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the granting of marketing authorization for Biocon’s pertuzumab biosimilar.
The European recommendation covers Pebrilzo® as a 420 mg/14 mL concentrate solution for infusion, intended for the treatment of HER2-positive breast cancer across multiple stages of the disease.
The CHMP recommendation represents an important development in the product’s international regulatory journey. The committee evaluates medicines for use across the European Union and provides scientific recommendations that support the European Commission’s final marketing authorization decisions.
The positive opinion also highlights Biocon’s progress in advancing its biosimilar development strategy through regulatory pathways in major pharmaceutical markets. Securing regulatory recommendations and approvals in both Europe and the United States can strengthen the commercial potential of a biosimilar product and support its introduction into additional healthcare markets, subject to applicable regulatory and commercial requirements.
Biocon’s European regulatory progress is particularly relevant given the increasing importance of biosimilars in oncology. Biologic cancer therapies have transformed treatment approaches for several difficult-to-treat cancers, but their cost can create challenges for patients, healthcare providers and reimbursement systems. Biosimilar development offers an opportunity to introduce additional treatment choices and potentially improve affordability and competition.
For Biocon, the positive CHMP opinion and U.S. FDA approval represent complementary achievements in its strategy to expand the global reach of its oncology portfolio.
Global Patent Settlement Establishes U.S. Launch Timeline
Alongside the regulatory developments, Biocon has also announced a global settlement and license agreement with Genentech concerning its pertuzumab biosimilar.
Under the agreement, Biocon has secured an earliest licensed launch date for Pebrilzo in the United States in the third quarter of calendar year 2028.
The agreement represents an important commercial development for the product, providing greater clarity regarding its potential U.S. market entry timeline. Patent settlements and licensing arrangements can play a significant role in determining when biosimilar products may enter the market, particularly in therapeutic areas where established biologic medicines are protected by extensive intellectual property portfolios.
By reaching an agreement with Genentech, Biocon has established a defined pathway toward the future U.S. commercialization of Pebrilzo. The planned Q3 2028 launch timeline provides the company with an opportunity to prepare its commercial strategy, manufacturing capabilities, supply chain and market access activities ahead of the anticipated introduction.
The agreement also reflects the importance of intellectual property considerations in the biosimilar industry. Although biosimilars are developed to provide highly similar alternatives to reference biologic medicines, their commercialization requires careful consideration of patent protections, regulatory requirements and licensing arrangements.
For Biocon, securing the earliest licensed launch date is an important step in translating its regulatory progress into future commercial opportunities.
Biocon Continues to Expand Its Oncology Biosimilar Portfolio
The approval of Pebrilzo further strengthens Biocon’s established oncology portfolio, which includes several commercially available biosimilar and biologic products targeting different cancer-related treatment needs.
With Pebrilzo, Biocon’s oncology portfolio includes:
- Ogivri® (trastuzumab-dkst): A biosimilar to trastuzumab, used in the treatment of certain HER2-positive cancers.
- Jobevne® (bevacizumab-nwgd): A biosimilar to bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein involved in the development of blood vessels that supply tumors.
- Fulphila® (pegfilgrastim-jmdb): A biosimilar to pegfilgrastim, used to reduce the risk of infection associated with chemotherapy-induced neutropenia.
- Aukelso® (denosumab-kyqq): A denosumab biosimilar that expands the company’s portfolio of biologic therapies.
- Pebrilzo™ (pertuzumab-qcay): A biosimilar to Perjeta, targeting HER2-positive breast cancer.
These products demonstrate the breadth of Biocon’s oncology strategy, which covers targeted cancer therapies and supportive treatments used in cancer care.
The company’s approach focuses on developing biosimilar medicines that address established treatment needs while expanding access to biologic therapies. Its oncology portfolio includes products with different mechanisms of action, allowing Biocon to participate in multiple segments of the cancer treatment market.
The addition of pertuzumab is especially relevant because HER2-targeted therapies represent an important component of modern breast cancer treatment. By strengthening its presence in this area, Biocon is further positioning itself in a major oncology market where biologic medicines play a central role.
Growing Oncology Pipeline Focuses on Targeted Therapy and Immuno-Oncology
In addition to its marketed oncology products, Biocon continues to invest in the development of a broader pipeline of proposed biosimilars.
The company’s growing oncology pipeline includes proposed biosimilar candidates to trastuzumab/hyaluronidase, nivolumab and pembrolizumab. These programs reflect its continued focus on established biologic treatments and emerging opportunities across targeted oncology and immuno-oncology.
Trastuzumab/hyaluronidase combines trastuzumab with hyaluronidase, an enzyme that facilitates the subcutaneous administration of certain biologic medicines. Trastuzumab targets HER2 and is widely used in the treatment of HER2-positive cancers.
Nivolumab and pembrolizumab are immune checkpoint inhibitors that target programmed cell death protein 1 (PD-1). These therapies work by helping the immune system recognize and attack cancer cells. PD-1 inhibitors have become important treatment options across several cancer types and have contributed to the development of modern immuno-oncology treatment approaches.
The inclusion of these proposed biosimilars in Biocon’s pipeline highlights its ambition to expand beyond its existing commercial portfolio and participate in additional high-value oncology treatment segments.
The development of biosimilars to established immunotherapies and targeted cancer medicines could create further opportunities to improve treatment accessibility, depending on successful development, regulatory approvals, intellectual property considerations and market conditions.
Through its commercial portfolio and pipeline programs, Biocon aims to build a diversified oncology business that addresses different treatment requirements across cancer care.
HER2-Positive Breast Cancer Represents a Significant Treatment Need
HER2-positive breast cancer is a distinct subtype of breast cancer characterized by overexpression of the human epidermal growth factor receptor 2 protein and/or amplification of the HER2 gene.
HER2 is a protein found on the surface of cells that helps regulate normal cell growth and division. In certain breast cancers, excessive HER2 activity can promote uncontrolled cell proliferation, contributing to more aggressive tumor development.
Approximately 20% of breast cancers are classified as HER2-positive. This subtype has historically been associated with faster disease progression and a greater risk of recurrence compared with some other forms of breast cancer. However, the development of HER2-targeted medicines has significantly improved treatment options and outcomes for many patients.
Pertuzumab is an important component of HER2-directed treatment strategies. It binds to a different region of the HER2 receptor than trastuzumab, helping prevent receptor pairing and interrupting signaling pathways that contribute to cancer cell growth. It is used in combination treatment regimens for eligible patients with HER2-positive breast cancer.
The availability of additional biosimilar versions of established HER2-targeted medicines could support greater competition and potentially improve access to these important therapies.
Breast Cancer Burden Highlights the Need for Affordable Treatments
Breast cancer continues to represent a major public health challenge in the United States and worldwide.
According to the estimates cited by Biocon, approximately 320,000 women in the United States are expected to be diagnosed with breast cancer in 2026. Around 20% of these diagnoses are expected to involve HER2-positive breast cancer.
The broader lifetime risk of breast cancer also underscores the scale of the disease burden, with approximately one in eight women expected to develop breast cancer during their lifetime.
Beyond the clinical challenges, breast cancer can create substantial financial and emotional pressures for patients and their families. Treatment may involve surgery, chemotherapy, radiation therapy, targeted biologic medicines and other supportive interventions, depending on the stage and characteristics of the disease.
The cost of advanced biologic treatments can create additional challenges, particularly for patients requiring prolonged treatment or combination therapies. This makes the development of high-quality biosimilars an important component of efforts to improve the sustainability and accessibility of cancer care.
Biocon’s investment in oncology biosimilars is aligned with this broader healthcare need. By expanding its portfolio of targeted biologic medicines, the company aims to support greater treatment availability while contributing to the development of more competitive markets for established therapies.
Strengthening Biocon’s Global Biosimilars Strategy
The FDA approval of Pebrilzo marks another important step in Biocon’s strategy to expand its global biosimilars business. As its fifth oncology biosimilar to receive U.S. FDA approval, the product reinforces the company’s capabilities in developing and advancing complex biologic medicines.
The combination of U.S. regulatory approval, positive European CHMP opinion and a global licensing agreement with Genentech provides an important foundation for the product’s future development and commercialization.
With its existing oncology portfolio and proposed biosimilar candidates targeting HER2 and PD-1 pathways, Biocon continues to build a diversified presence in the oncology market.
The company remains focused on expanding access to high-quality biologic medicines and addressing unmet treatment needs across major therapeutic areas. The addition of Pebrilzo strengthens this strategy and represents another milestone in Biocon’s efforts to contribute to more accessible and affordable cancer treatment worldwide.
About PEBRILZO (pertuzumab-qcay)
The approval for PEBRILZO (pertuzumab-qcay) was based on a comprehensive package containing structural and functional analytical characterization, analytical similarity, and comparative clinical pharmacokinetic data, which confirmed that PEBRILZO is highly similar to the reference biologics, Perjeta® with no clinically meaningful differences in quality, safety, efficacy, and immunogenicity.


